[go: up one dir, main page]

BRPI0914305B8 - compostos de piridazina carboxamida substituída como compostos inibidores da quinase, uso dos compostos e uso de uma composição compreendendo os compostos - Google Patents

compostos de piridazina carboxamida substituída como compostos inibidores da quinase, uso dos compostos e uso de uma composição compreendendo os compostos

Info

Publication number
BRPI0914305B8
BRPI0914305B8 BRPI0914305A BRPI0914305A BRPI0914305B8 BR PI0914305 B8 BRPI0914305 B8 BR PI0914305B8 BR PI0914305 A BRPI0914305 A BR PI0914305A BR PI0914305 A BRPI0914305 A BR PI0914305A BR PI0914305 B8 BRPI0914305 B8 BR PI0914305B8
Authority
BR
Brazil
Prior art keywords
compounds
kinase inhibitor
composition
substituted carboxamide
pyridazine
Prior art date
Application number
BRPI0914305A
Other languages
English (en)
Inventor
Liang Congxin
Li Zhigang
Original Assignee
Xcovery Holding Co Llc
Xcovery Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xcovery Holding Co Llc, Xcovery Holdings Inc filed Critical Xcovery Holding Co Llc
Publication of BRPI0914305A2 publication Critical patent/BRPI0914305A2/pt
Publication of BRPI0914305B1 publication Critical patent/BRPI0914305B1/pt
Publication of BRPI0914305B8 publication Critical patent/BRPI0914305B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

compostos de piridazina carboxamida substituída como compostos inibidores da quinase os derivados de piridazina têm propriedades de droga inesperadas como inibidores da proteína quinase e são úteis no tratamento de distúrbios relacionados a atividades anormais da proteína quinase, tais como câncer.
BRPI0914305A 2008-06-19 2009-06-18 compostos de piridazina carboxamida substituída como compostos inibidores da quinase, uso dos compostos e uso de uma composição compreendendo os compostos BRPI0914305B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13250508P 2008-06-19 2008-06-19
US61/132,505 2008-06-19
PCT/US2009/003654 WO2009154769A1 (en) 2008-06-19 2009-06-18 Substituted pyridazine carboxamide compounds as kinase inhibitor compounds

Publications (3)

Publication Number Publication Date
BRPI0914305A2 BRPI0914305A2 (pt) 2015-08-11
BRPI0914305B1 BRPI0914305B1 (pt) 2021-05-11
BRPI0914305B8 true BRPI0914305B8 (pt) 2021-05-25

Family

ID=41434356

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914305A BRPI0914305B8 (pt) 2008-06-19 2009-06-18 compostos de piridazina carboxamida substituída como compostos inibidores da quinase, uso dos compostos e uso de uma composição compreendendo os compostos

Country Status (15)

Country Link
US (3) US8697866B2 (pt)
EP (2) EP2303018B1 (pt)
JP (1) JP5670325B2 (pt)
KR (1) KR101691640B1 (pt)
CN (1) CN102098917B (pt)
AU (1) AU2009260810B2 (pt)
BR (1) BRPI0914305B8 (pt)
CA (1) CA2728408C (pt)
ES (2) ES2551899T3 (pt)
IL (1) IL210099A (pt)
MX (1) MX2010014171A (pt)
NZ (1) NZ590542A (pt)
PL (1) PL2303018T3 (pt)
RU (1) RU2526618C2 (pt)
WO (1) WO2009154769A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102098917B (zh) * 2008-06-19 2016-03-16 艾科睿控股公司 作为激酶抑制剂化合物的取代的哒嗪羧酰胺化合物
ES2589792T3 (es) * 2010-03-23 2016-11-16 Basf Se Compuestos de piridazina para el control de plagas de invertebrados
JP6023062B2 (ja) * 2010-10-08 2016-11-09 エックスカバリー ホールディング カンパニー エルエルシー 置換ピリダジンカルボキサミド化合物
CN103298803A (zh) * 2010-10-08 2013-09-11 艾科睿控股公司 作为激酶抑制剂化合物的取代的哒嗪羧酰胺化合物
WO2014048939A1 (en) 2012-09-26 2014-04-03 F. Hoffmann-La Roche Ag Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
CN102952091A (zh) * 2012-10-19 2013-03-06 盛世泰科生物医药技术(苏州)有限公司 一种4-氨基异恶唑盐酸盐的合成方法
RU2550346C2 (ru) * 2013-09-26 2015-05-10 Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
TWI646094B (zh) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
BR112021001263A2 (pt) * 2018-07-24 2021-04-27 Epizyme, Inc. compostos, seus usos, método para tratar câncer e método para modular uma atividade de smarca2
WO2020128020A2 (de) * 2018-12-21 2020-06-25 Saltigo Gmbh Verfahren zur herstellung von 2-alkoxy-4-amino-5-methyl-pyridinen und/oder von 2-alkoxy-4-alkylamino-5-methyl-pyridinen
CN112457268A (zh) * 2020-12-11 2021-03-09 平江县吉成科技有限责任公司 一种温和的4-氨基异恶唑盐酸盐的合成方法
CN116082110B (zh) * 2023-01-09 2024-04-12 北京肿瘤医院(北京大学肿瘤医院) 一种11c标记靶向间变性淋巴瘤激酶alk突变分子探针及应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
ATE66143T1 (de) 1985-01-11 1991-08-15 Abbott Lab Feste zubereitung mit langsamer freisetzung.
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
WO2000006128A1 (fr) 1998-07-28 2000-02-10 Tanabe Seiyaku Co., Ltd. Preparation capable de liberer un medicament au niveau d'un site cible dans l'intestin
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
KR20040053130A (ko) * 2001-09-21 2004-06-23 일라이 릴리 앤드 캄파니 무스카린성 효능제
US6800663B2 (en) 2002-10-18 2004-10-05 Alkermes Controlled Therapeutics Inc. Ii, Crosslinked hydrogel copolymers
JP4695588B2 (ja) 2003-02-26 2011-06-08 スージェン， インク． プロテインキナーゼ阻害剤としてのアミノヘテロアリール化合物
UA84175C2 (ru) * 2003-11-19 2008-09-25 Аррей Байофарма Инк. Гетероциклические ингибиторы мэк и их применение
GEP20094845B (en) 2004-08-26 2009-11-25 Pfizer Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
CA2578075A1 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
WO2006033005A2 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Thrombopoietin receptor agonists
BRPI0516915A (pt) * 2004-12-01 2008-03-11 Devgen Nv derivados de tiazol substituìdos por 5-carboxamido que interagem com canais de ìons, particularmante com canais de ìons da famìlia kv
WO2007053189A2 (en) * 2005-06-01 2007-05-10 Northwestern University Compositions and methods for altering immune function
US7745477B2 (en) * 2006-02-07 2010-06-29 Hoffman-La Roche Inc. Heteroaryl and benzyl amide compounds
US7772233B2 (en) 2006-04-19 2010-08-10 Merck Serono, S.A. Arylamino N-heteroaryl compounds as MEK inhibitors
ES2531002T3 (es) * 2007-01-19 2015-03-09 Xcovery Inc Compuestos inhibidores de quinasa
TW200918521A (en) * 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
CN102098917B (zh) * 2008-06-19 2016-03-16 艾科睿控股公司 作为激酶抑制剂化合物的取代的哒嗪羧酰胺化合物
EP2427458B1 (en) * 2009-05-05 2014-05-07 F.Hoffmann-La Roche Ag Isoxazole-pyridazine derivatives
US8669254B2 (en) * 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents

Also Published As

Publication number Publication date
US20160176900A1 (en) 2016-06-23
EP2303018A4 (en) 2012-06-20
AU2009260810B2 (en) 2015-09-17
RU2526618C2 (ru) 2014-08-27
US20110160209A1 (en) 2011-06-30
KR101691640B1 (ko) 2016-12-30
CN102098917A (zh) 2011-06-15
RU2011139352A (ru) 2013-04-10
WO2009154769A1 (en) 2009-12-23
JP5670325B2 (ja) 2015-02-18
NZ590542A (en) 2012-12-21
PL2303018T3 (pl) 2016-06-30
IL210099A (en) 2015-11-30
US9296724B2 (en) 2016-03-29
AU2009260810A1 (en) 2009-12-23
BRPI0914305A2 (pt) 2015-08-11
EP2303018B1 (en) 2015-10-14
US8697866B2 (en) 2014-04-15
BRPI0914305B1 (pt) 2021-05-11
ES2670665T3 (es) 2018-05-31
IL210099A0 (en) 2011-02-28
EP3061752B1 (en) 2018-02-21
MX2010014171A (es) 2011-07-04
EP2303018A1 (en) 2011-04-06
ES2551899T3 (es) 2015-11-24
US20140221376A1 (en) 2014-08-07
CA2728408C (en) 2017-12-05
CN102098917B (zh) 2016-03-16
KR20110044974A (ko) 2011-05-03
EP3061752A1 (en) 2016-08-31
JP2011524905A (ja) 2011-09-08
CA2728408A1 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
BRPI0914305B8 (pt) compostos de piridazina carboxamida substituída como compostos inibidores da quinase, uso dos compostos e uso de uma composição compreendendo os compostos
BRPI0807146B8 (pt) compostos inibidores da atividade da akt, seu uso no tratamento de câncer e artrite, bem como composição farmacêutica compreendendo os mesmos
WO2008074997A8 (en) Pyridine benzamides and pyrazine benzamides used as pkd inhibitors
EP2381775A4 (en) INHIBITORS OF NECROPTOSIS OF SMALL MOLECULAR SIZE
MX2010009207A (es) Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
MX340714B (es) Inhibidores de hsp90.
MA32393B1 (fr) Composés et compositions servant d'inhibiteurs de kinases
BR112014008495B8 (pt) Composto inibidor da proteína quinase, composição farmacêutica compreendendo-o e uso do mesmo para a fabricação de um medicamento para o tratamento de câncer
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
UA111272C2 (uk) Конденсовані піримідинові похідні для інгібування тирозинкіназної активності
MX2009011950A (es) Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr.
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
BR112013008523A2 (pt) compostos de piridazina carboxamida substituídos
BRPI0919447B8 (pt) compostos derivados de ácido 1-amino-2- ciclobutiletilborônico, composição farmacêutica e uso dos mesmos para tratar câncer
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
BRPI0613859B8 (pt) inibidores da comt, seus usos, e composição farmacêutica
MX384206B (es) Formulaciones de inhibidores de dpp iv
EA201501088A1 (ru) Гетероарильные соединения, применяемые в качестве ингибиторов e1 активирующих ферментов
UA99617C2 (ru) Производные пирролконденсированного азотсодержащего гетероцикла, их получение и фармацевтическое применение
ATE489371T1 (de) Benzamidglucokinaseaktivatoren
CL2008003265A1 (es) Compuestos derivados de heterociclos nitrogenados, supresores de la produccion de colageno; composicion farmaceutica que comprende dichos compuestos; y su uso para prevenir y/o tratar la fibrosis y/o los tumores.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: XCOVERY HOLDING COMPANY LLC (US)

Free format text: A FIM DE ATENDER A(S) ALTERACAO(OES) DE NOME REQUERIDA(S) ATRAVES DA PETICAO NO870200054923 DE 04/05/2020, E NECESSARIO:1. ESCLARECER A DIVERGENCIA QUE HA ENTRE O ENDERECO APRESENTADO NA PETICAO SUPRA E OENDERECO DA TITULAR, CONFORME PETICAO 020100118583 DE 20/12/2010;2. APRESENTAR GRU REFERENTE AO CUMPRIMENTO DA PRESENTE EXIGENCIA.

B25D Requested change of name of applicant approved

Owner name: XCOVERY HOLDINGS, INC. (US)

B25G Requested change of headquarter approved

Owner name: XCOVERY HOLDINGS, INC. (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/06/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/06/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF